The Slamf3, Slamf5, and Slamf6 receptor-induced pathways to murine lupus

$350,959P01FY2016AINIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Paper 36902453 Paper 31057553 Paper 30482849 Paper 30058241 Paper 28980301 Paper 28751772 Paper 28076903 Paper 27992687 Paper 27695002 Paper 27581174 Paper 27482100 Paper 27368806 Paper 27183584 Paper 27029059 Paper 26794910 Paper 26667173 Paper 26339044 Paper 26314831 Paper 25957267 Paper 25926831 Paper 25801878 Paper 25799045 Paper 25678452 Paper 25456769 Paper 25347469 Paper 24941157 Paper 24795728 Paper 24670806 Paper 23629864 Paper 23225888 Paper 22989874 Paper 22768209 Paper 22613797 Paper 22184727 Paper 22088620 Paper 21983784 Paper 21622868 Paper 21561736 Paper 21422172 Paper 21298027 Paper 21278219 Paper 21231893 Paper 20962259 Paper 20818396 Paper 20706608 Paper 20628063 Paper 20609249 Paper 20458333 Paper 20228799 Paper 20146065 Paper 19784369 Paper 19426211 Paper 19387462 Paper 19217684 Paper 19098911 Paper 18852889 Paper 18852199 Paper 18654571 Paper 18495325 Paper 18445119 Paper 18437207 Paper 18272545 Paper 18216865 Paper 18059267 Paper 17997607 Paper 16080120

Abstract

PROJECT SUMMARY (See instructions): SLAMF receptors and their adapters SAP and EAT-2 play a major role in human and mouse innate and adaptive immune response. Investigators in this Program Project have discovered that in mice several of these receptors either positively or negatively regulate the development of autoimmunity, including lupus related pathology. Excitingly, preliminary studies have revealed deviations in signaling pathways initiated by several SLAMF receptors in immunocytes isolated from patients with systemic lupus erythematosus (SLE). The overall hypothesis of Project #1 is that the mouse receptors Slamf3, 5, and 6 and their isoforms govern immune responses involved in the pathogenesis of murine lupus. The experiments that are designed to test this hypothesis are grouped as follows: Specific Aim#1: Testing the hypothesis that the three Slamf6 receptor isoforms initiate distinct positive and negative regulatory pathways to lupus. Specific Aim #2: Testing the hypothesis that the Slamf5 receptor governs signaling in T and B cells and DC during the pathogenesis of mouse lupus. Specific Aim #3: Testing the hypothesis that Slamf3 receptor initiated signaling controls autoantibody production.

View original record on NIH RePORTER →